ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- A Macrophage/Monocyte-Related Four-Gene Signature for Prognostic Assessment of Uveal Melanoma:Human mutation · 2026Article
- Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.Nature biomedical engineering · 2024Article
- Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation.Frontiers in immunology · 2023Article
- Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.Frontiers in immunology · 2022Review
- Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.Cancers · 2021Article
- Adaptive T cell immunotherapy in cancer.Science China. Life sciences · 2021Review
- Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.ACS applied materials & interfaces · 2021Article
- Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.Cellular & molecular immunology · 2020Review
- Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.Journal for immunotherapy of cancer · 2020Article
- A transplantable tumor model allowing investigation of NY-BR-1-specific T cell responses in HLA-DRB1*0401 transgenic mice.BMC cancer · 2019Article
- Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer.Cureus · 2018Review
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.Melanoma research · 2018Review
- Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.Journal for immunotherapy of cancer · 2018Article
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.Journal of hematology & oncology · 2018Review
- Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Frontiers in immunology · 2017Review
- The Role of Tumor Microenvironment in Cancer Immunotherapy.Advances in experimental medicine and biology · 2017Review
- Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.Cancer immunology, immunotherapy : CII · 2016Article
- Chimeric antigen receptor T-cell therapy for solid tumors.Molecular therapy oncolytics · 2016Review
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.Frontiers in oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Immunotherapeutic approaches to the treatment of advanced melanoma have relied on strategies that augment the responsiveness of endogenous tumor-specific T-cell populations [eg, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade-mediated checkpoint inhibition] or introduce exogenously prepared tumor-specific T-cell populations [eg, adoptive cell transfer (ACT)]. Although both approaches have shown considerable promise, response rates to these therapies remain suboptimal. We hypothesized that a combinatorial approach to immunotherapy using both CTLA-4 blockade and nonlymphodepletional ACT could offer additive therapeutic benefit. C57BL/6 mice were inoculated with syngeneic B16F10 melanoma tumors transfected to express low levels of the lymphocytic choriomeningitis virus peptide GP33 (B16GP33), and treated with no immunotherapy, CTLA-4 blockade, ACT, or combination immunotherapy of CTLA-4 blockade with ACT. Combination immunotherapy resulted in optimal control of B16GP33 melanoma tumors. Combination immunotherapy promoted a stronger local immune response reflected by enhanced tumor-infiltrating lymphocyte populations, and a stronger systemic immune responses reflected by more potent tumor antigen-specific T-cell activity in splenocytes. In addition, whereas both CTLA-4 blockade and combination immunotherapy were able to promote long-term immunity against B16GP33 tumors, only combination immunotherapy was capable of promoting immunity against parental B16F10 tumors as well. Our findings suggest that a combinatorial approach using CTLA-4 blockade with nonlymphodepletional ACT may promote additive endogenous and exogenous T-cell activities that enable greater therapeutic efficacy in the treatment of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.